Literature DB >> 22785517

The appearance of pulmonary mucormycosis on FDG PET/CT.

Chun-Jiang Dang1, Ya-Jun Li, Feng-Hua Zhan, Xiao-Ming Shang.   

Abstract

Pulmonary mucormycosis is a life-threatening opportunistic mycosis that is difficult to diagnose early. We report the case of a 56-year-old woman who complained of intermittent fever in the afternoon and productive cough and pain on the right side of the chest. Her clinical condition deteriorated despite antibiotherapy. FDG PET/CT showed a heterogeneous soft tissue mass at the lower part of the right lung with obvious FDG uptake in the peripheral part of the mass. Mucormycosis was proven by histopathology and fungal culture from the transbronchial lung biopsy materials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785517     DOI: 10.1097/RLU.0b013e31825ae470

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

1.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

Review 2.  Imaging fungal infections in children.

Authors:  Alfred O Ankrah; Mike M Sathekge; Rudi A J O Dierckx; Andor W J M Glaudemans
Journal:  Clin Transl Imaging       Date:  2016-01-25

3.  Lung Masses of Unusual Histologies Mimicking Malignancy: Flurodeoxyglucose Positron Emission Tomography-Computed Tomography Appearance.

Authors:  Boon Mathew; Nilendu C Purandare; Sneha Shah; Ameya Puranik; Archi Agrawal; Venkatesh Rangarajan
Journal:  Indian J Nucl Med       Date:  2019 Oct-Dec

Review 4.  COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.

Authors:  Rachel Samson; Mahesh Dharne
Journal:  3 Biotech       Date:  2021-12-06       Impact factor: 2.893

Review 5.  PET in the diagnostic management of infectious/inflammatory pulmonary pathologies: a revisit in the era of COVID-19.

Authors:  Sanaz Katal; Hamidreza Amini; Ali Gholamrezanezhad
Journal:  Nucl Med Commun       Date:  2021-01       Impact factor: 1.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.